Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-28
2006-11-28
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S183000
Reexamination Certificate
active
07141571
ABSTRACT:
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
REFERENCES:
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 6787545 (2004-09-01), Ohtani et al.
patent: 6867300 (2005-03-01), Godfrey, Jr. et al.
patent: 6869952 (2005-03-01), Bhide et al.
patent: 6908916 (2005-06-01), Mastalerz et al.
patent: 6916815 (2005-07-01), Vite et al.
patent: 2003/0232832 (2003-12-01), Lombardo et al.
patent: 2003/0232861 (2003-12-01), Dyckman et al.
patent: 2004/0063707 (2004-04-01), Bhide et al.
patent: 2004/0063708 (2004-04-01), Bhide et al.
patent: 2004/0077858 (2004-04-01), Bhide et al.
patent: 2004/0229877 (2004-11-01), Leftheris et al.
patent: 0 713 876 (1996-05-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 02/40486 (2002-05-01), None
patent: WO 03/090912 (2003-11-01), None
patent: WO 2004/009784 (2004-01-01), None
Tsi-Ping et al., TIPS 16:5766, 1995.
U.S. Appl. No. 60/620,784, filed Oct. 21, 2004, Gavai et al.
U.S. Appl. No. 11/152,650, filed Jun. 14, 2005, Cai et al.
U.S. Appl. No. 11/157,460, filed Jun. 21, 2005, Gavai et al.
U.S. Appl. No. 11,008,719, filed Dec. 9, 2004, Swaminathan et al.
U.S. Appl. No. 11/019,899, filed Dec. 22, 2004, Gavai et al.
Ewald, H. et al., “Reaktionen von 1,2,4-Triazinen mit Acetylendicarbonsäure-dimethylester”, Liebigs Ann. Chem., pp. 1718-1724 (1977).
Hunt, J.T. et al., “Discovery of the Pyrrolo[2,1-f][1,2,4]triazine Nucleus as a New Kinase Inhibitor Template”, J. Med. Chem., vol. 47, No. 16, pp. 4054-4059 (2004).
Migliara, O. et al., “Synthesis of a New Bridgehead Nitrogen Heterocyclic System. Pyrrolo[2,1-f]-1,2,4—triazine Derivatives”, J. Heterocyclic Chem., vol. 16, pp. 833-834 (1979).
Neunhoeffer, H. et al., “Cycloadditionen mit Methoxy- und Dialkylamino-1,2,4-triazinen”, Liebigs Ann. Chem., pp. 1413-1420 (1977).
Patil, S.A. et al., “Synthesis of Pyrrolo[2,1-f][1,2,4]triazine Congeners of Nucleic Acid Purines via the N-Amination of 2-Substituted Pyrroles”, J. Heterocyclic Chem., vol. 31, pp. 781-786 (1994).
Quintela, J.M. et al., “A Ready One-pot Preparation for Pyrrolo[2,1-f][1,2,4]triazine and Pyrazolo[5,1-c]pyrimido[4,5-e]-[1,2,4]traizine Derivatives”, Tetrahedron, vol. 52, No. 8, pp. 3037-3048 (1996).
Chen Ping
Fink Brian E.
Gavai Ashvinikumar V.
Han Wen-Ching
Mastalerz Harold
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Korsen Elliot
LandOfFree
Pyrrolotriazine compounds as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolotriazine compounds as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolotriazine compounds as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3651372